NEX-22A, a prolonged release formulation of liraglutide
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
May 27, 2024 → Jul 18, 2025
NCT ID
NCT06439056About NEX-22A, a prolonged release formulation of liraglutide
NEX-22A, a prolonged release formulation of liraglutide is a phase 1 stage product being developed by Nanexa AB for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT06439056. Target conditions include Type 2 Diabetes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06439056 | Phase 1 | Completed |
Competing Products
20 competing products in Type 2 Diabetes